HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acyl-CoA Oxidase

An enzyme that catalyzes the first and rate-determining steps of peroxisomal beta-oxidation of fatty acids. It acts on COENZYME A derivatives of fatty acids with chain lengths from 8 to 18, using FLAVIN-ADENINE DINUCLEOTIDE as a cofactor.
Also Known As:
Acyl Coenzyme A Oxidase; Fatty Acid Acyl-CoA Oxidase; Fatty Acyl-CoA Oxidase; Fatty Acyl-Coenzyme A Oxidase; Acyl CoA Oxidase; Acyl-CoA Oxidase, Fatty; Fatty Acid Acyl CoA Oxidase; Fatty Acyl CoA Oxidase; Fatty Acyl Coenzyme A Oxidase; Oxidase, Acyl-CoA; Oxidase, Fatty Acyl-CoA
Networked: 154 relevant articles (1 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Reddy, J K: 6 articles (06/2012 - 03/2000)
2. Reddy, Janardan K: 6 articles (08/2011 - 01/2002)
3. Rao, M Sambasiva: 4 articles (08/2011 - 12/2002)
4. Cherkaoui-Malki, Mustapha: 3 articles (06/2012 - 08/2007)
5. Jia, Yuzhi: 3 articles (08/2011 - 12/2002)
6. Rao, M S: 3 articles (08/2001 - 03/2000)
7. Espinosa, Alejandra: 2 articles (10/2018 - 06/2014)
8. Valenzuela, Rodrigo: 2 articles (10/2018 - 06/2014)
9. Videla, Luis A: 2 articles (10/2018 - 06/2014)
10. Kim, Hye Min: 2 articles (01/2017 - 01/2015)

Related Diseases

1. Glucose Intolerance
2. Adrenoleukodystrophy (Adrenoleukodystrophy, X-Linked)
06/03/1991 - "Immunoblot analyses of peroxisomal beta-oxidation enzymes showed that subunit A of acyl-CoA oxidase gave a stronger immunoreaction in fibroblasts of Zellweger and X-linked adrenoleukodystrophy patients than in those of controls. "
04/01/2015 - "A diagnostic protocol was developed to determine for each newborn with a positive screen whether the final diagnosis is X-ALD, carrier of X-ALD, Zellweger spectrum disorder, acyl CoA oxidase deficiency or D-bifunctional protein deficiency. "
02/01/1999 - "We found that expression of both acyl-CoA oxidase, the rate limiting enzyme of peroxisomal VLCFA beta-oxidation and the adrenoleukodystrophy protein (ALDP), the defective gene product in X-ALD, are reduced after SV40T transformation. "
02/01/1999 - "Impaired peroxisomal beta-oxidation of saturated very long chain fatty acids (VLCFA, >/=C22:0) results in increased VLCFA levels in the tissues and body fluids of patients with disorders of peroxisomal biogenesis (i.e., Zellweger syndrome and neonatal adrenoleukodystrophy) and single peroxisomal protein defects (i.e., X-linked adrenoleukodystrophy (X-ALD) and acyl-CoA oxidase deficiency). "
03/01/1987 - "Very long chain fatty acids, which accumulate in plasma and tissues in X-linked adrenoleukodystrophy (ALD), neonatal ALD, and the Zellweger cerebrohepatorenal syndrome, are degraded by the peroxisomal beta-oxidation pathway, consisting of acyl-CoA oxidase, the bifunctional enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase, and beta-ketothiolase. "
3. Obesity
08/01/2010 - "Most of the obesity candidate genes were closely connected through lipid metabolism, and in particular acyl-coenzyme A oxidase 1 appeared to be a core obesity gene. "
04/01/2016 - "The decreased expression of sterol regulatory element-binding proteins 1C (SREBP-1c), acetyl-CoA carboxylase (ACC), and fatty acid synthase (FAS)-reduced lipid synthesis; Activation of peroxisome proliferator-activator receptor (PPARα) accompanied by increase of uncoupling protein2 (UP2) and acyl-CoA oxidase (AOX) stimulated lipid metabolism and exerted an antiobesity effect via increasing energy expenditure for prevention of obesity. "
01/01/2014 - "This study reveals novel findings such as the divergent expression of the fatty acid β-oxidation enzymes Acyl-CoA oxidase 1 and Carnitine palmitoyltransferase 1a, indicating a switch from mitochondrial to peroxisomal β-oxidation after weaning; as well as the dynamic ontogeny of genes implicated in obesity such as Stearoyl-CoA desaturase 1 and Elongation of very long chain fatty acids-like 3. These data shed new light on the ontogeny of homeostatic regulation of hepatic energy metabolism, which could ultimately provide new therapeutic targets for metabolic diseases. "
08/01/2011 - "Thirty-two Yorkshire gilts were allotted to two treatment groups of control (C folic acid 1.3 mg/kg) or folic acid supplementation (FS folic acid 30 mg/kg) after mating, to study the effects of maternal folic acid supplementation on the mRNA expression of methionine adenosyltransferase (MAT), cystathionine-β-synthase (CBS), methylenetetrahydrofolate reductase (MTHFR), DNA methyltransferase1 (DNMT1), peroxisomal proliferator-activated receptor (PPARγ), glucocorticoid receptor (GR), obesity receptor (ob-R) and Acyl-CoA oxidase (AOX) in the liver of IUGR and NBW piglets. "
4. Hepatocellular Carcinoma (Hepatoma)
5. Peroxisomal Disorders (Peroxisomal Disorder)

Related Drugs and Biologics

1. Fatty Acids (Saturated Fatty Acids)
2. Messenger RNA (mRNA)
3. Carnitine O-Palmitoyltransferase (Carnitine Palmitoyltransferase II)
4. Peroxisome Proliferator-Activated Receptors (PPAR)
5. Stearoyl-CoA Desaturase
6. Fatty Acid Synthases (Fatty Acid Synthase)
7. Triglycerides (Triacylglycerol)
8. Sterols
9. Elements
10. Diacylglycerol O-Acyltransferase

Related Therapies and Procedures

1. Fat-Restricted Diet (Diet, Fat Restricted)
2. Aftercare (After-Treatment)
3. bitter melon extract